Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 3/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 13/20 | 0.40 |
| ▸ | CD38 | P28907 | 1/20 | 0.39 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20399088 | 0.95 | CCR4 (0.40) | CCR4PTK2CD38PIP4K2C | |
| SCHEMBL20399565 | 0.90 | EPHX2 (0.45) | CCR4PTK2PIP4K2C | |
| SCHEMBL21541982 | 0.88 | ACHE (0.47) | CCR4PTK2CD38PIP4K2CACHE | |
| SCHEMBL20399105 | 0.88 | CCR4 (0.45) | CCR4CD38PIP4K2CACHEPDE5A | |
| SCHEMBL21541986 | 0.88 | CCR4 (0.42) | CCR4PTK2CD38 | |
| SCHEMBL26743380 | 0.87 | CCR4 (0.45) | CCR4PTK2ACHEPDE5AHRH4 | |
| SCHEMBL21541983 | 0.86 | CCR4 (0.44) | CCR4CD38PIP4K2CACHEPDE5A | |
| SCHEMBL20399161 | 0.86 | CCR4 (0.47) | CCR4CD38PIP4K2CACHEPDE5A | |
| SCHEMBL26743237 | 0.86 | CCR4 (0.44) | CCR4PTK2ACHEPDE5AHRH4 | |
| SCHEMBL20399571 | 0.85 | CCR4 (0.45) | CCR4CD38PIP4K2CACHEPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240108629-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2024-04-04 | — | — | US | claimed |
| EP-4277631-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | Liverpool School of Tropical Medicine (GB) | 2023-11-22 | — | — | EP | claimed |
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2022-12-06 | — | — | US | claimed |
| WO-2022152918-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2022-07-21 | — | — | WO | claimed |
| US-20190345157-A1 | COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-11-14 | — | — | US | claimed |
| US-12545675-B2 | Anti-wolbachia pyrido[2,3-d]pyrimidine compounds | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2026-02-10 | — | — | US | disclosed |
| US-20240108629-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2024-04-04 | — | — | US | disclosed |
| EP-4277631-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | Liverpool School of Tropical Medicine (GB) | 2023-11-22 | — | — | EP | disclosed |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-11-02 | — | — | US | disclosed |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-11-02 | — | — | US | disclosed |
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2022-12-06 | — | — | US | disclosed |
| WO-2022152918-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2022-07-21 | — | — | WO | disclosed |
| US-20190345157-A1 | COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-11-14 | — | — | US | disclosed |
| US-20190345157-A1 | COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545675-B2 | Anti-wolbachia pyrido[2,3-d]pyrimidine compounds | CBR1, CBR3, COX6C | CCR4 101/4885PTK2 2589/4885CD38 1803/4885 |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | PWWP2B, WARS1, PNPO | CCR4 3571/4885PTK2 2209/4885CD38 3007/4885 |
| US-20190345157-A1 | COMPOUNDS | ABCB11, LTC4S, AQP1 | CCR4 752/4885PTK2 2780/4885CD38 1870/4885 |
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | P2RX5, PNPO, P2RX3 | CCR4 3139/4885PTK2 2267/4885CD38 2960/4885 |
| US-20240108629-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | AQP3, AQP1, AQP4 | CCR4 2777/4885PTK2 4744/4885CD38 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.